The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-10

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In our study, we aimed to investigate how whole blood viscosity (WBV) affects the development of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

NCT01878344

Acute ST Segment Elevation Myocardial Infarction

ACTIVE_NOT_RECRUITING PHASE3

Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction

NCT01160627

Contrast Induced Nephropathy

COMPLETED NA

Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients

NCT04730778

Acute ST Segment Elevation Myocardial Infarction

COMPLETED

Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement

NCT03121053

Aortic Valve Disease Chronic Kidney Disease Contrast Induced Nephropathy +1 more

UNKNOWN PHASE4

Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions

NCT02468401

Kidney Disease, Chronic Ischemic Heart Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In our study, 500 patients who applied to the cardiology clinic and underwent PCI for elective procedure, ST segment elevation myocardial infarction (STEMI), and non-STEMI were prospectively included. Before the procedure, we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Percutaneous Coronary Intervention Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Viscosity Testing

we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients between ages 18 and 90
* underwent PCI in our hospital between

Exclusion Criteria

* Patients with chronic kidney disease (CKD) who underwent hemodialysis or peritoneal dialysis
* Patients who underwent to coronary bypass surgery within 48 h were excluded from the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No